SRDX (Surmodics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by SRDX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-11-19 | John D. Manders | VP Finance, Corp. Controller | D | — | — |
| 2025-11-19 | Joseph J. Stich | SVP of HR, President IVD | D | — | — |
| 2025-11-19 | JOSE H BEDOYA | Director | D | — | — |
| 2025-11-19 | Timothy J. Arens | Chief Financial Officer | D | — | — |
| 2025-11-19 | Gary R Maharaj | President & CEO | D | — | — |
| 2025-11-19 | CHARLES W OLSON | SVP, Medical Device Coatings | D | — | — |
| 2025-11-19 | DAVID DANTZKER | Director | D | — | — |
| 2025-11-19 | Lisa Wipperman Heine | Director | D | — | — |
| 2025-11-19 | Gordon S. Weber | Sr. VP of Legal, GC and Sec. | D | — | — |
| 2025-11-19 | SUSAN E KNIGHT | Director | D | — | — |
| 2025-11-19 | TERI WOODWICK SIDES | SVP, Vascular Interventions | D | — | — |
| 2025-02-20 | Lisa Wipperman Heine | Director | MIXED | — | — |
| 2025-02-18 | JOSE H BEDOYA | Director | MIXED | — | — |
| 2025-02-18 | DAVID DANTZKER | Director | MIXED | — | — |
| 2025-01-28 | SUSAN E KNIGHT | Director | MIXED | — | — |
| 2024-12-06 | Joseph J. Stich | SVP of HR, President IVD | F | — | — |
| 2024-12-06 | Timothy J. Arens | Chief Financial Officer | F | — | — |
| 2024-12-06 | John D. Manders | VP Finance, Corp. Controller | F | — | — |
| 2024-12-06 | Gordon S. Weber | Sr. VP of Legal, GC and Sec. | F | — | — |
| 2024-12-06 | CHARLES W OLSON | SVP, Medical Device Coatings | F | — | — |
| 2024-12-06 | TERI WOODWICK SIDES | SVP, Vascular Interventions | F | — | — |
| 2024-12-06 | Gary R Maharaj | President & CEO | F | — | — |
| 2024-12-03 | Timothy J. Arens | Chief Financial Officer | F | — | — |
| 2024-12-03 | Joseph J. Stich | SVP of HR, President IVD | F | — | — |
| 2024-12-03 | TERI WOODWICK SIDES | SVP, Vascular Interventions | F | — | — |
| 2024-12-03 | CHARLES W OLSON | SVP, Medical Device Coatings | F | — | — |
| 2024-12-03 | Gordon S. Weber | Sr. VP of Legal, GC and Sec. | F | — | — |
| 2024-12-03 | John D. Manders | VP Finance, Corp. Controller | F | — | — |
| 2024-12-03 | Gary R Maharaj | President & CEO | F | — | — |
| 2024-11-27 | Timothy J. Arens | Chief Financial Officer | Sell | — | — |
| 2024-08-23 | Gary R Maharaj | President & CEO | MIXED | — | — |
| 2024-08-23 | Joseph J. Stich | SVP of HR, President IVD | MIXED | — | — |
| 2024-08-20 | CHARLES W OLSON | SVP, Medical Device Coatings | MIXED | — | — |
| 2024-08-20 | Timothy J. Arens | Chief Financial Officer | MIXED | — | — |
| 2024-02-12 | DAVID DANTZKER | Director | A | — | — |
| 2024-02-12 | RONALD B SR KALICH | Director | A | — | — |
| 2024-02-12 | JOSE H BEDOYA | Director | MIXED | — | — |
| 2024-02-12 | SUSAN E KNIGHT | Director | A | — | — |
| 2024-02-12 | Lisa Wipperman Heine | Director | A | — | — |
| 2024-02-07 | SUSAN E KNIGHT | Director | MIXED | — | — |
| 2024-01-23 | DAVID DANTZKER | Director | MIXED | — | — |
| 2024-01-03 | RONALD B SR KALICH | Director | A | — | — |
| 2023-12-29 | RONALD B SR KALICH | Director | MIXED | — | — |
| 2023-12-06 | Gordon S. Weber | Sr. VP of Legal, GC and Sec. | A | — | — |
| 2023-12-06 | Gary R Maharaj | President & CEO | A | — | — |
| 2023-12-06 | John D. Manders | Corporate Controller | A | — | — |
| 2023-12-06 | CHARLES W OLSON | SVP, Medical Device Coatings | A | — | — |
| 2023-12-06 | Joseph J. Stich | SVP HR and IVD | A | — | — |
| 2023-12-06 | TERI WOODWICK SIDES | SVP, Vascular Interventions | A | — | — |
| 2023-12-06 | Timothy J. Arens | Chief Financial Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 1,406,667 | — |
| — | 10%+ Owner | 453,178 | — |
| — | President & CEO | 82,255 | — |
| — | VP of Research | 59,017 | — |
| — | Director | 38,278 | — |
| — | SVP, Gen Counsel & Secretary | 36,411 | — |
| — | Interim CEO, Senior VP & CFO | 36,369 | — |
| — | VP & Chief Scientific Officer | 33,867 | — |
| — | Director | 31,227 | — |
| — | COO of Medical Devices | 30,013 | — |
| — | Director | 26,800 | — |
| — | VP of Research and Development | 26,363 | — |
| — | VP of Finance & CFO | 20,486 | — |
| — | Sr VP/Gen Mgr Orth/Chf IP Cnsl | 19,943 | — |
| — | VP, Pres of Pharmaceuticals | 17,317 | — |
| — | Vice President and Controller | 16,869 | — |
| — | VP, President - Ophthamology | 16,645 | — |
| — | Director | 15,557 | — |
| — | Director | 14,199 | — |
| — | Director | 11,672 | — |
| — | Sr VP, Product Development | 10,665 | — |
| — | Director | 9,210 | — |
| — | VP of HR | 8,390 | — |
| — | Corporate Controller | 6,957 | — |
| — | VP, Clinical Affairs | 6,530 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SRDX quote page; the site-wide leaderboard is on the insider transactions hub.